Products
Online Inquiry
iCRT 14
Cat. No.:
OB0225WX-1707
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
iCRT 14 is a novel and potent inhibitor of β-catenin-responsive transcription (CRT), demonstrating a half-maximal inhibitory concentration (IC50) of 40.3 nM in Wnt pathway activity assays.
Synonym:
677331-12-3; iCRT-14; iCRT14; (5Z)-5-[(2,5-dimethyl-1-pyridin-3-ylpyrrol-3-yl)methylidene]-3-phenyl-1,3-thiazolidine-2,4-dione; (5Z)-5-{[2,5-Dimethyl-1-(3-pyridinyl)-1H-pyrrol-3-yl]methylene}-3-phenyl-1,3-thiazolidine-2,4-dione; (5Z)-5-{[2,5-dimethyl-1-(pyridin-3-yl)-1H-pyrrol-3-yl]methylidene}-3-phenyl-1,3-thiazolidine-2,4-dione; 5-[[2,5-Dimethyl-1-(3-pyridinyl)-1H-pyrrol-3-yl]methylene]-3-phenyl-2,4-thiazolidinedione; iCRT 14; iCRT14; CRT Inhibitor iCRT14; 5-((2,5-Dimethyl-1-(pyridin-3-yl)-1H-pyrrol-3-yl)methylene)-3-phenylthiazolidine-2,4-dione
CAS No.:
677331-12-3
Compound CID:
5967294
Formula:
C21H17N3O2S
Formula Weight:
375.44
Specification
Targets&IC50:
Wnt responsive STF16 luciferase: 40.3 nM
Relative Density:
1.29 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
iCRT 14 is applied in oncological research to examine the targeted inhibition of the beta-catenin/TCF4 complex and its impact on the proliferation of Wnt-dependent cancer cells.
Library Information
Target:
Wnt/β-Catenin
Receptor:
Wnt
Pathways:
Stem cells; Cytoskeletal signaling
Plate Number:
AOCL-22
Plate Location:
h2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
12 mg/mL; 31.96 mM
ALogP:
3.741
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
3
